Sandra Re

Sandra Re, MD, MBA, currently serves as Senior Medical Director for Oncology Clinical Development at Daiichi Sankyo, Inc., a position held since November 2023. Prior to this role, Sandra Re was with Bristol Myers Squibb from July 2016 to November 2023, where responsibilities included serving as Senior Director and Global Clinical Development Lead for Farletuzumab Ecteribulin, along with various roles encompassing clinical trial leadership and medical publications. Earlier experience includes positions at the University of North Carolina at Chapel Hill, where Sandra Re contributed to clinical research within maternal-fetal medicine and gestational diabetes. Sandra Re's educational background includes an MBA in Strategy from NYU Stern School of Business and a Doctor of Medicine from Universidad Austral in Buenos Aires.